Profusa, Inc. Common Stock (PFSA) Stock Price & Analysis
Profusa, Inc. Common Stock (PFSA) — MoonshotScore 29/100 (Weak band), calculated Nov 18, 2026. Price $0.3455 (-2.51%), as of the Nov 19, 2026 trading session; market cap $1.96M.
Educational signal · not a buy or sell recommendation · How to read this
Profusa, Inc. Common Stock · PFSA · NASDAQ
Profusa, Inc. is a digital-health company focused on developing tissue-integrating biosensors. Their Lumee™ Oxygen Platform aims to continuously monitor body chemistry and provide AI-powered health insights for chronic conditions.
Price as of Nov 19, 2026
Key Statistics
MoonshotScore v2 · Profusa, Inc. Common Stock (PFSA)
WeakWhy this rating? Method, drivers & history
Bands for the MoonshotScore: Exceptional 80-100 · Strong 65-79 · Fair 45-64 · Weak below 45.
- Business Quality — Is this a genuinely good business?
- Financial Safety — Could this blow up on me?
- Valuation — Am I paying a fair price?
- Growth Durability — Is the growth real and likely to last?
- Momentum — Is the market already moving on this?
A fragile balance sheet, stalling growth and an expensive valuation, though quality is only middling, and the price trend has turned against it. The score also carries a risk penalty for a bankruptcy-risk score in the distress zone. Business Quality: Average; Financial Safety: Fragile; Valuation: Bubble; Growth Durability: Fading; Momentum: Falling.
Free cash flow yield is the main valuation drag relative to sector peers.
- Altman Z -11.64 · Piotroski F 2
- ROE 148.2% · current ratio 0.03
Holding back: balance-sheet strain, a rich price, soft growth, weak price trend
What has the MoonshotScore done over time?
| Recorded | Score | Band |
|---|---|---|
| 27 | Weak | |
| 27 | Weak | |
| 27 | Weak | |
| 27 | Weak | |
| 29 | Weak | |
| 29 | Weak |
Daily score refresh is delayed. This is the last recorded calculation.
Calculation uses the most recent completed US trading session. Live price changes do not update the score immediately.
Computed · How the MoonshotScore is computed →
Price & valuation
| Measure | Value | As of |
|---|---|---|
| Latest provided price | $0.3455 | |
| Change on the day | -2.51% | |
| 52-week range | $0.3455 – $1537.50 | |
| Market capitalisation | $1.96M | — |
| Shares traded on the day | 573.9K |
Price & events
Other perspectives
Council score for Profusa, Inc. Common Stock (PFSA): perspectives
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
5-Factor Breakdown
Legends Council
6 lenses, 0 current
AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Read on: Sep 9, 2026 · older than the 27 hours refresh window; not a current reading
Munger's Mindset
Balance Sheet & Valuation · historical
Read on: Jun 27, 2026 · older than the 27 hours refresh window; not a current reading
How to read these bars and different assessments
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.
On Jun 27, 2026, the Munger lens read the price at that time as fairly valued against its own estimate of value.
Readings on this page are from Nov 20, 2026, except a card that shows its own read date.
What is Profusa, Inc. Common Stock (PFSA), and what does it report?
Short answer
A current FMP business description is unavailable; the listing and provider classification below are the available identity facts. Profusa, Inc. Common Stock (PFSA) is listed on NASDAQ. It employs 2 people and is led by Jack E. Stover. The market values it at $1.96M.
What are the financial strengths and risks for Profusa, Inc. Common Stock (PFSA)?
Short answer · as of
What is holding it back is balance-sheet strain, a rich price, soft growth, weak price trend. The distress and quality screens read Altman Z -11.64 · Piotroski F 2. Trailing ratios: ROE 148.2% · current ratio 0.03.
Data-derived red flags
- Listing risk — at $0.3455 the shares sit below the $1.00 minimum bid NASDAQ requires for continued listing.
- Financial-distress signal — its Altman Z-Score of -11.64 sits in the distress zone (elevated bankruptcy risk).
- Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
How does Profusa, Inc. Common Stock compare with its peers?
Short answer
Profusa, Inc. Common Stock's score ranks 13th of 13 in the bounded comparison shown, against 12 same-model peers. These are company scores, not expected investment returns. The set lists named competitors first, then companies in the same data-provider industry classification closest in market value; that classification is the provider's, not our judgment of business similarity.
| Company | Price | Market value | Score |
|---|---|---|---|
| $23.40 Nov 18, 2026 | $191M | 87 5-pillar Nov 18, 2026 | |
| $13.28 Nov 19, 2026 | $178M | 71 5-pillar Nov 18, 2026 | |
| $4.85 Nov 18, 2026 | $59.6M | 44 5-pillar Nov 18, 2026 | |
| $1.03 Nov 19, 2026 | $6.24M | 43 5-pillar Nov 18, 2026 | |
| $1.66 Nov 19, 2026 | $104M | 43 5-pillar Nov 18, 2026 | |
| $3.67 Nov 18, 2026 | $110M | 41 5-pillar Nov 18, 2026 | |
| $2.38 Nov 18, 2026 | $36.2M | 39 5-pillar Nov 18, 2026 | |
| $5.42 Nov 19, 2026 | $141M | 37 5-pillar Nov 18, 2026 | |
| $6.34 Nov 19, 2026 | $258M | 36 5-pillar Nov 18, 2026 | |
| $2.49 Nov 18, 2026 | $105M | 33 5-pillar Nov 18, 2026 | |
| $0.49 Nov 19, 2026 | $7.00M | 32 5-pillar Nov 18, 2026 | |
| $4.84 Nov 19, 2026 | $7.78M | 31 5-pillar Nov 18, 2026 | |
| Profusa, Inc. Common Stock (PFSA) — this page | $0.3455 | $1.96M | 29 |
Only 5-pillar scores are ranked together. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.
The records behind this page
Insider activity
Form 4 records via FMP · Of the newest 100 records, those within the last 180 days, newest dated Aug 21, 2026
- Transactions
- 20
- Identified insiders
- 3
- Purchases
- 8
- Sales
- 6
- Other transactions
- 6
Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.
Who holds the shares?
Institutional ownership reported through 13F filings.
Tracked investors
Which of the 16 named investors we follow held PFSA in their latest 13F filing, and what they did against the filing before it.
None of the 16 tracked investors reported PFSA in their latest 13F filing.
How to read these figures
These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.
What has been published about Profusa, Inc. Common Stock (PFSA)?
- Profusa Reports Third Quarter 2026 Financial Results
- Profusa Announces Progress Toward Closing Option Agreement with G3 Vision Labs
- Profusa Says Near Closure Of Option Agreement With G3 Vision Labs, Including Receipt Of G3’s FY24 And FY25 Financial Statements; G3 Took Net Loss In FY25
- Profusa Announces Progress Towards Satisfying the Conditions to Close of the Option Agreement with G3
Investor Questions: PFSA Stock
These answers are editorial: 1 of these 9 answers is drawn from the PFSA research dossier (written Mar 16, 2026 by gemini-2.0-flash); the other 8 are question templates that restate figures shown above. Figures in this section are not part of the source register.
What does the MoonshotScore mean for PFSA?
PFSA carries the MoonshotScore stated above — the Weak band. This is an educational research signal, not a buy or sell recommendation. The number comes from the five-pillar engine (business quality, financial safety, valuation, growth durability, momentum), re-ranked daily against sector peers. Profusa, Inc. is a digital-health company focused on developing tissue-integrating biosensors.
Is PFSA a good stock to buy?
Stock Expert AI does not rate PFSA buy, sell or hold. Profusa, Inc. Common Stock carries a MoonshotScore, in the Weak band, a research rating against its peers rather than a forecast. Whether it fits is your call: check what it sells, whether it earns and what the price assumes. This is educational content, not investment advice.
What is the PFSA stock price today?
The last price recorded for Profusa, Inc. Common Stock (PFSA), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.
How does Profusa, Inc. Common Stock navigate regulatory approval processes?
As a medical device company, Profusa, Inc. must navigate stringent regulatory approval processes in the United States and other markets.
What are the key factors to evaluate for PFSA?
Profusa, Inc. Common Stock (PFSA) holds a MoonshotScore in the low range. The Lumee™ Oxygen Platform is designed to provide AI-powered health insights for chronic conditions. Not financial advice.
How frequently does PFSA data refresh on this page?
PFSA's price is the last quote we recorded, from the Nov 19, 2026 trading session. Pages are served from a cache, so the copy you are reading can lag that quote. The quote is a provider snapshot, not an exchange feed. Fundamentals follow quarterly filings. V2 is recalculated from the most recent completed US trading session; the score's own date shows its last successful run.
What has driven PFSA's recent stock price performance?
Profusa, Inc. Common Stock (PFSA) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Innovative tissue-integrating biosensor technology. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider PFSA overvalued or undervalued right now?
Profusa, Inc. Common Stock (PFSA) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
Can I buy fractional shares of PFSA?
Fractional-share availability for Profusa, Inc. Common Stock (PFSA) depends on your brokerage, account and supported securities. Check the broker's current eligibility, minimums and fees before placing an order.
Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated Mar 16, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.
Sources: the source register lists the 13 figures on this page — 5 from Financial Modeling Prep (FMP), 6 with no recorded source and 2 from Stock Expert AI's own score and rank. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.
Publication details and research sources
- Published
- Research standards
- Methodology · Editorial policy · Corrections
- Report a number
- sedat@stockexpertai.com